InvestSMART

Alterity Therapeutics Limited (ASX: ATH) - Announcements

Current share price for ATH : $0.575 0.025 (4.17%)+

ASX company news and announcements for Alterity Therapeutics Limited (ATH) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Alterity Therapeutics Limited (ATH) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Alterity Therapeutics Limited (ATH), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Alterity Therapeutics Limited (ATH)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$125 Presentation to Annual General Meeting 21 Nov 2025 10:45AM $0.009 $0.575 risen by 6,288.89%
$125 Chairman's Address 2025 Annual General Meeting 21 Nov 2025 10:35AM $0.009 $0.575 risen by 6,288.89%
$125 Alterity Board Changes 21 Nov 2025 9:20AM $0.009 $0.575 risen by 6,288.89%
$125 Disclosure under Takeovers Panel GN 20 13 Nov 2025 12:58PM $0.009 $0.575 risen by 6,288.89%
$125 Alterity to Present at the Bell Potter Healthcare Conference 12 Nov 2025 11:17AM $0.009 $0.575 risen by 6,288.89%
$125 Alterity Presents Promising ATH434 Impact at AAS Symposium 10 Nov 2025 10:41AM $0.009 $0.575 risen by 6,288.89%
$125 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2025 9:30AM $0.011 $0.575 risen by 5,127.27%
$125 Notice of Annual General Meeting/Proxy Form 21 Oct 2025 2:24PM $0.012 $0.575 risen by 4,691.67%
$125 Change in substantial holding 14 Oct 2025 4:50PM $0.011 $0.575 risen by 5,127.27%
$125 Alterity Presents Positive ATH434 Data at 2025 MDS Congress 9 Oct 2025 10:56AM $0.010 $0.575 risen by 5,650%
$125 Alterity to Deliver Multiple Presentations at MDS Conference 2 Oct 2025 8:32AM $0.009 $0.575 risen by 6,288.89%
$125 Alterity Reports New Commercial Assessment for ATH434 in MSA 29 Sep 2025 12:26PM $0.010 $0.575 risen by 5,650%
$125 Date of AGM and Closing Date for Director Nominations 23 Sep 2025 5:12PM $0.011 $0.575 risen by 5,127.27%
$125 Change of Director's Interest Notice x 4 17 Sep 2025 3:28PM $0.011 $0.575 risen by 5,376.19%
$125 Notification of cessation of securities - ATH 17 Sep 2025 12:10PM $0.010 $0.575 risen by 5,650%
$125 Change in substantial holding 17 Sep 2025 8:21AM $0.010 $0.575 risen by 5,650%
$125 Alterity Presents Phase 2 Data at US Neurology Meeting 15 Sep 2025 11:05AM $0.012 $0.575 risen by 4,691.67%
$125 Notice Under Section 708A 15 Sep 2025 9:16AM $0.013 $0.575 risen by 4,500%
$125 Application for quotation of securities - ATH 15 Sep 2025 9:11AM $0.013 $0.575 risen by 4,500%
$125 Proposed issue of securities - ATH 8 Sep 2025 9:47AM $0.013 $0.575 risen by 4,323.08%
$125 Alterity Raises A$20.0 million in Strategic Placement 8 Sep 2025 9:47AM $0.013 $0.575 risen by 4,323.08%
$125 Trading Halt 4 Sep 2025 9:09AM $0.013 $0.575 risen by 4,323.08%
$125 Trading Halt 4 Sep 2025 9:09AM $0.013 $0.575 risen by 4,323.08%
$125 Alterity Therapeutics Filed Form 20-F and XBRL Data with SEC 2 Sep 2025 11:17AM $0.014 $0.575 risen by 4,007.14%
$125 Alterity Therapeutics to Present at the Biotech Showcase 1 Sep 2025 10:06AM $0.013 $0.575 risen by 4,323.08%

51 - 75 of 547 results

Page 3 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.